Dg. Kiely et al., CARDIOPULMONARY INTERACTIONS OF SALBUTAMOL AND HYPOXEMIA IN HEALTHY-YOUNG VOLUNTEERS, British journal of clinical pharmacology, 40(4), 1995, pp. 313-318
1 Nebulised salbutamol is frequently used in the treatment of asthma a
nd chronic obstructive pulmonary disease. Its effects on the cardiovas
cular system have been extensively investigated although as yet little
is known concerning its effects on the pulmonary circulation, particu
larly during hypoxaemia. We have therefore examined the effects of neb
ulised salbutamol on pulmonary haemodynamics to see if it modifies hyp
oxic pulmonary vasoconstriction. 2 Eight healthy normal volunteers wer
e studied on two separate occasions. After resting to achieve baseline
haemodynamics patients were randomised to receive 5 mg salbutamol or
placebo via a nebuliser. They were restudied after 30 min and then ren
dered hypoxaemic by breathing an N-2/O-2 mixture to achieve an SaO(2)
of 75-80%. Doppler echocardiography was used to measure mean pulmonary
artery pressure (MPAP), cardiac output (CO) and hence pulmonary vascu
lar resistance (PVR). 3 Treatment with salbutamol significantly increa
sed MPAP during normoxaemia and hypoxaemia compared with placebo at 12
.0 +/- 1.2 vs 8.0 +/- 0.7 mm Hg and 28.6 +/- 0.9 vs 25.2 +/- 1.0 mm Hg
, respectively (P < 0.05). Salbutamol caused a significant increase in
heart rate compared with placebo and effects were additive to those o
f hypoxia at 74 +/- 2 vs 67 +/- 3 beats min(-1) during normoxaemia and
84 +/- 3 vs 77 +/- 4 beats min(-1) during hypoxaemia, respectively (P
< 0.05). Whilst systemic vascular resistance fell in response to salb
utamol, PVR was unchanged by salbutamol during either normoxaemia or h
ypoxaemia. Cardiac output was increased by salbutamol and by hypoxia.
4 Since PVR was not altered by salbutamol, this suggests that changes
in CO rather than true pulmonary vasoconstriction were responsible for
the observed increase in MPAP with salbutamol during normoxaemia and
hypoxaemia. Thus, there appears to be no significant interaction betwe
en salbutamol and hypoxia in the human pulmonary vasculature, although
combined chronotropic effects may be important.